Switch to:
Also traded in: Austria, Germany, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.18
HOLX's Cash-to-Debt is ranked lower than
85% of the 205 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.74 vs. HOLX: 0.18 )
Ranked among companies with meaningful Cash-to-Debt only.
HOLX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04  Med: 2.12 Max: No Debt
Current: 0.18
0.04
No Debt
Equity-to-Asset 0.35
HOLX's Equity-to-Asset is ranked lower than
77% of the 196 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. HOLX: 0.35 )
Ranked among companies with meaningful Equity-to-Asset only.
HOLX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.02  Med: 0.69 Max: 0.88
Current: 0.35
0.02
0.88
Debt-to-Equity 1.34
HOLX's Debt-to-Equity is ranked lower than
85% of the 142 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.37 vs. HOLX: 1.34 )
Ranked among companies with meaningful Debt-to-Equity only.
HOLX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0  Med: 0.24 Max: 10
Current: 1.34
0
10
Debt-to-EBITDA 15.24
HOLX's Debt-to-EBITDA is ranked higher than
51% of the 109 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.88 vs. HOLX: 15.24 )
Ranked among companies with meaningful Debt-to-EBITDA only.
HOLX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -103.43  Med: 2.77 Max: 15.24
Current: 15.24
-103.43
15.24
Interest Coverage 3.44
HOLX's Interest Coverage is ranked lower than
76% of the 137 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 63.92 vs. HOLX: 3.44 )
Ranked among companies with meaningful Interest Coverage only.
HOLX' s Interest Coverage Range Over the Past 10 Years
Min: 1  Med: 2.38 Max: 4.44
Current: 3.44
1
4.44
Piotroski F-Score: 4
Altman Z-Score: 1.32
Beneish M-Score: -2.47
WACC vs ROIC
6.93%
1.79%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 16.15
HOLX's Operating Margin % is ranked higher than
97% of the 201 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.41 vs. HOLX: 16.15 )
Ranked among companies with meaningful Operating Margin % only.
HOLX' s Operating Margin % Range Over the Past 10 Years
Min: 10.7  Med: 16.35 Max: 22.51
Current: 16.15
10.7
22.51
Net Margin % -2.47
HOLX's Net Margin % is ranked higher than
95% of the 201 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.18 vs. HOLX: -2.47 )
Ranked among companies with meaningful Net Margin % only.
HOLX' s Net Margin % Range Over the Past 10 Years
Min: -135.4  Med: -1.5 Max: 24.7
Current: -2.47
-135.4
24.7
ROE % -2.88
HOLX's ROE % is ranked higher than
96% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.43 vs. HOLX: -2.88 )
Ranked among companies with meaningful ROE % only.
HOLX' s ROE % Range Over the Past 10 Years
Min: -60.17  Med: -0.73 Max: 30.67
Current: -2.88
-60.17
30.67
ROA % -1.03
HOLX's ROA % is ranked higher than
87% of the 206 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.85 vs. HOLX: -1.03 )
Ranked among companies with meaningful ROA % only.
HOLX' s ROA % Range Over the Past 10 Years
Min: -32.08  Med: -0.35 Max: 9.88
Current: -1.03
-32.08
9.88
ROC (Joel Greenblatt) % -36.76
HOLX's ROC (Joel Greenblatt) % is ranked higher than
99% of the 204 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.63 vs. HOLX: -36.76 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
HOLX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -369.68  Med: 25.23 Max: 205.21
Current: -36.76
-369.68
205.21
3-Year Revenue Growth Rate 5.60
HOLX's 3-Year Revenue Growth Rate is ranked higher than
55% of the 170 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. HOLX: 5.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
HOLX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -14.1  Med: 9.55 Max: 41.9
Current: 5.6
-14.1
41.9
3-Year EBITDA Growth Rate 31.10
HOLX's 3-Year EBITDA Growth Rate is ranked higher than
79% of the 155 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.00 vs. HOLX: 31.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
HOLX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 128.9
Current: 31.1
0
128.9
3-Year EPS without NRI Growth Rate 253.00
HOLX's 3-Year EPS without NRI Growth Rate is ranked higher than
99% of the 155 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 12.90 vs. HOLX: 253.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
HOLX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 371.8
Current: 253
0
371.8
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» HOLX's 30-Y Financials

Financials (Next Earnings Date: 2018-11-08)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

HOLX Guru Trades in Q3 2017

Jerome Dodson 476,556 sh (New)
Ken Fisher 12,225 sh (New)
John Hussman 50,000 sh (New)
Paul Tudor Jones 7,981 sh (New)
Steven Cohen 1,064,085 sh (New)
Joel Greenblatt 313,189 sh (+660.15%)
Lee Ainslie 139,580 sh (+57.70%)
Robert Olstein 119,700 sh (+30.82%)
Vanguard Health Care Fund 3,538,200 sh (unchged)
Pioneer Investments Sold Out
Caxton Associates Sold Out
Kahn Brothers 731,816 sh (-8.46%)
Chuck Royce 12,700 sh (-36.50%)
Jim Simons 501,838 sh (-59.10%)
Eaton Vance Worldwide Health Sciences Fund 419,549 sh (-14.68%)
» More
Q4 2017

HOLX Guru Trades in Q4 2017

Pioneer Investments 165,604 sh (New)
Robert Olstein 147,700 sh (+23.39%)
Steven Cohen 1,306,179 sh (+22.75%)
Jerome Dodson 540,734 sh (+13.47%)
Vanguard Health Care Fund 4,014,000 sh (+13.45%)
John Hussman Sold Out
Chuck Royce Sold Out
Lee Ainslie Sold Out
Jim Simons Sold Out
Paul Tudor Jones Sold Out
Joel Greenblatt Sold Out
Kahn Brothers 691,667 sh (-5.49%)
Ken Fisher 10,638 sh (-12.98%)
Eaton Vance Worldwide Health Sciences Fund 202,173 sh (-51.81%)
» More
Q1 2018

HOLX Guru Trades in Q1 2018

Jim Simons 247,418 sh (New)
Ray Dalio 20,164 sh (New)
Caxton Associates 18,731 sh (New)
Pioneer Investments 1,521,695 sh (+818.88%)
Ken Fisher 16,400 sh (+54.16%)
Jerome Dodson 746,734 sh (+38.10%)
Robert Olstein 167,700 sh (+13.54%)
Vanguard Health Care Fund 4,386,300 sh (+9.28%)
Eaton Vance Worldwide Health Sciences Fund Sold Out
Kahn Brothers 657,997 sh (-4.87%)
Steven Cohen 450,000 sh (-65.55%)
» More
Q2 2018

HOLX Guru Trades in Q2 2018

Paul Tudor Jones 6,934 sh (New)
Larry Robbins 1,229,620 sh (New)
Steven Cohen 2,409,618 sh (+435.47%)
Pioneer Investments 2,392,183 sh (+57.21%)
Vanguard Health Care Fund 4,927,800 sh (+12.35%)
Jerome Dodson 811,734 sh (+8.70%)
Ken Fisher 16,400 sh (unchged)
Steven Cohen 300,000 sh (unchged)
Ray Dalio Sold Out
Jim Simons Sold Out
Kahn Brothers 611,027 sh (-7.14%)
Robert Olstein 128,000 sh (-23.67%)
Caxton Associates 5,926 sh (-68.36%)
» More
» Details

Insider Trades

Latest Guru Trades with HOLX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2018-06-30 Add 12.35%0.05%$36.43 - $40.46 $ 41.237%4,927,800
Kahn Brothers 2018-06-30 Reduce -7.14%0.28%$36.43 - $40.46 $ 41.237%611,027
Robert Olstein 2018-06-30 Reduce -23.67%0.19%$36.43 - $40.46 $ 41.237%128,000
Vanguard Health Care Fund 2018-03-31 Add 9.28%0.03%$37.26 - $44.42 $ 41.232%4,386,300
Kahn Brothers 2018-03-31 Reduce -4.87%0.23%$37.26 - $44.42 $ 41.232%657,997
Robert Olstein 2018-03-31 Add 13.54%0.1%$37.26 - $44.42 $ 41.232%167,700
Ken Fisher 2018-03-31 Add 54.16%$37.26 - $44.42 $ 41.232%16,400
Vanguard Health Care Fund 2017-12-31 Add 13.45%0.05%$35.9 - $43.82 $ 41.233%4,014,000
Kahn Brothers 2017-12-31 Reduce -5.49%0.22%$35.9 - $43.82 $ 41.233%691,667
Robert Olstein 2017-12-31 Add 23.39%0.15%$35.9 - $43.82 $ 41.233%147,700
Ken Fisher 2017-12-31 Reduce -12.98%$35.9 - $43.82 $ 41.233%10,638
Joel Greenblatt 2017-12-31 Sold Out 0.17%$35.9 - $43.82 $ 41.233%0
Kahn Brothers 2017-09-30 Reduce -8.46%0.47%$36.65 - $45.41 $ 41.232%731,816
Joel Greenblatt 2017-09-30 Add 660.15%0.15%$36.65 - $45.41 $ 41.232%313,189
Robert Olstein 2017-09-30 Add 30.82%0.13%$36.65 - $45.41 $ 41.232%119,700
Ken Fisher 2017-09-30 New Buy$36.65 - $45.41 $ 41.232%12,225
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 334517    SIC: 3844
Compare:XSWX:STMN, NYSE:COO, NAS:XRAY, TSE:7733, NYSE:RMD, NYSE:STE, NYSE:MTD, NYSE:WAT, SZSE:002294, NYSE:WST, NYSE:HRC, NAS:ICUI, NAS:PODD, NYSE:CMD, TSE:7747, NYSE:HAE, MIL:AMP, OCSE:COLO B, OSTO:LIFCO B, ASX:ANN » details
Traded in other countries:HOLX.Austria, HO1.Germany, 0J5Q.UK,
Headquarter Location:USA
Hologic Inc develops, manufactures and supplies diagnostics products, medical imaging systems and surgical products for women's health. Its products are used in diagnosis of human diseases and screen donated human blood and plasma.

Hologic Inc manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (47% of sales), breast health (37%), surgical (12%), and skeletal health (4%). While the company traditionally focused on breast health, the recent acquisition of Gen-Probe puts a much greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (74%), followed by Europe (12%) and Asia (8%). Hologic is headquartered in Bedford, Massachusetts.

Guru Investment Theses on Hologic Inc

Jerome Dodson Comments on Hologic - Oct 25, 2017

Hologic (NASDAQ:HOLX) is a medical technology company focused on improving women’s health through early detection and treatment, including digital mammography and pap testing. In March, the company paid $1.65 billion to acquire Cynosure, a leader in aesthetic laser treatment. While early results from Cynosure have been disappointing, we believe Hologic has the management depth to turn its performance around. Meanwhile, we expect Hologic’s pipeline of innovative new products to widen its lead in women’s health.



From Jerome Dodson (Trades, Portfolio)'s Parnassus Fund third quarter 2017 commentary.

Check out Jerome Dodson latest stock trades

Top Ranked Articles about Hologic Inc

Hologic to Webcast Presentation at the Morgan Stanley 16th Annual Global Healthcare Conference
Research Report Identifies America's Car-Mart, SAExploration, Ascena Retail Group, Infinity Pharmaceuticals, Hologic, and California Resources with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
Final USPSTF Cervical Cancer Screening Recommendations Retain "A" Grade for Pap + HPV for Women Ages 30 to 65
Hologic Launches Fluent™ Fluid Management System for Hysteroscopic Procedures
Hologic's Cynosure Division Signs Agreement with Porter Instrument to Exclusively Distribute Nitrous Oxide and Oxygen System in Aesthetics Market
Jerome Dodson’s High-Conviction Trades as of 2nd Quarter Guru's portfolio lags S&P 500 benchmark on sector allocation headwinds
Jerome Dodson (Trades, Portfolio) disclosed in his second-quarter shareholder letter that the Parnassus Fund trailed the Standard & Poor’s 500 benchmark by approximately 2.4% for the quarter, primarily due to unfavorable sector allocation and poor results from Starbucks Corp. (NASDAQ:SBUX). As of June, the guru’s high-conviction trades include Starbucks and three other companies: Hologic Inc. (NASDAQ:HOLX), Mondelez International Inc. (NASDAQ:MDLZ) and Thompson Reuters Corp. (NYSE:TRI). Read more...
Hologic to Webcast Presentation at the Canaccord Genuity 38th Annual Growth Conference
Hologic Announces FDA Clearance of the Panther Fusion® GBS Assay
Hologic Announces Chief Financial Officer Change
Hologic to Acquire Faxitron Bioptics, Leader in Digital Specimen Radiography, for Approximately $85 Million

Ratios

vs
industry
vs
history
Forward PE Ratio 16.42
HOLX's Forward PE Ratio is ranked higher than
90% of the 40 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 26.32 vs. HOLX: 16.42 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 4.57
HOLX's PB Ratio is ranked higher than
51% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.45 vs. HOLX: 4.57 )
Ranked among companies with meaningful PB Ratio only.
HOLX' s PB Ratio Range Over the Past 10 Years
Min: 0.59  Med: 2 Max: 5.65
Current: 4.57
0.59
5.65
PS Ratio 3.59
HOLX's PS Ratio is ranked lower than
53% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.48 vs. HOLX: 3.59 )
Ranked among companies with meaningful PS Ratio only.
HOLX' s PS Ratio Range Over the Past 10 Years
Min: 1.47  Med: 2.93 Max: 5.12
Current: 3.59
1.47
5.12
Price-to-Free-Cash-Flow 20.53
HOLX's Price-to-Free-Cash-Flow is ranked lower than
99.99% of the 74 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 28.61 vs. HOLX: 20.53 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
HOLX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 6.52  Med: 14.79 Max: 32.12
Current: 20.53
6.52
32.12
Price-to-Operating-Cash-Flow 17.27
HOLX's Price-to-Operating-Cash-Flow is ranked lower than
100% of the 94 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.15 vs. HOLX: 17.27 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
HOLX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.51  Med: 12.99 Max: 928.86
Current: 17.27
5.51
928.86
EV-to-EBIT -52.09
HOLX's EV-to-EBIT is ranked higher than
91% of the 121 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.93 vs. HOLX: -52.09 )
Ranked among companies with meaningful EV-to-EBIT only.
HOLX' s EV-to-EBIT Range Over the Past 10 Years
Min: -53.9  Med: 24.8 Max: 153.7
Current: -52.09
-53.9
153.7
EV-to-EBITDA 64.83
HOLX's EV-to-EBITDA is ranked higher than
90% of the 138 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.49 vs. HOLX: 64.83 )
Ranked among companies with meaningful EV-to-EBITDA only.
HOLX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -32.4  Med: 13 Max: 73.7
Current: 64.83
-32.4
73.7
EV-to-Revenue 4.34
HOLX's EV-to-Revenue is ranked lower than
58% of the 199 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.57 vs. HOLX: 4.34 )
Ranked among companies with meaningful EV-to-Revenue only.
HOLX' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.6  Med: 4.2 Max: 10.1
Current: 4.34
2.6
10.1
Current Ratio 1.29
HOLX's Current Ratio is ranked lower than
83% of the 200 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.57 vs. HOLX: 1.29 )
Ranked among companies with meaningful Current Ratio only.
HOLX' s Current Ratio Range Over the Past 10 Years
Min: 0.79  Med: 2.79 Max: 7.31
Current: 1.29
0.79
7.31
Quick Ratio 0.99
HOLX's Quick Ratio is ranked lower than
78% of the 201 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.87 vs. HOLX: 0.99 )
Ranked among companies with meaningful Quick Ratio only.
HOLX' s Quick Ratio Range Over the Past 10 Years
Min: 0.61  Med: 2.2 Max: 6.57
Current: 0.99
0.61
6.57
Days Inventory 85.80
HOLX's Days Inventory is ranked higher than
74% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 124.35 vs. HOLX: 85.80 )
Ranked among companies with meaningful Days Inventory only.
HOLX' s Days Inventory Range Over the Past 10 Years
Min: 65.34  Med: 85.51 Max: 108.2
Current: 85.8
65.34
108.2
Days Sales Outstanding 62.79
HOLX's Days Sales Outstanding is ranked lower than
53% of the 165 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.97 vs. HOLX: 62.79 )
Ranked among companies with meaningful Days Sales Outstanding only.
HOLX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.15  Med: 60.73 Max: 74.61
Current: 62.79
56.15
74.61
Days Payable 40.34
HOLX's Days Payable is ranked lower than
65% of the 151 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 54.66 vs. HOLX: 40.34 )
Ranked among companies with meaningful Days Payable only.
HOLX' s Days Payable Range Over the Past 10 Years
Min: 21.81  Med: 27.28 Max: 45.11
Current: 40.34
21.81
45.11

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 0.30
HOLX's 3-Year Average Share Buyback Ratio is ranked higher than
85% of the 143 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -5.00 vs. HOLX: 0.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
HOLX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -53.1  Med: -6 Max: 0.3
Current: 0.3
-53.1
0.3

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.86
HOLX's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
68% of the 75 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.41 vs. HOLX: 1.86 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
HOLX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.45  Med: 1.72 Max: 13.86
Current: 1.86
0.45
13.86
Price-to-Median-PS-Value 1.23
HOLX's Price-to-Median-PS-Value is ranked lower than
57% of the 160 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.13 vs. HOLX: 1.23 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
HOLX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.15  Med: 0.84 Max: 2.58
Current: 1.23
0.15
2.58
Price-to-Peter-Lynch-Fair-Value 54.97
HOLX's Price-to-Peter-Lynch-Fair-Value is ranked lower than
99.99% of the 45 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.46 vs. HOLX: 54.97 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
HOLX' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0  Med: 3.41 Max: 55.21
Current: 54.97
0
55.21
Earnings Yield (Greenblatt) % -1.91
HOLX's Earnings Yield (Greenblatt) % is ranked higher than
95% of the 207 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.40 vs. HOLX: -1.91 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
HOLX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -49.1  Med: 2.6 Max: 10.6
Current: -1.91
-49.1
10.6
Forward Rate of Return (Yacktman) % 21.45
HOLX's Forward Rate of Return (Yacktman) % is ranked higher than
92% of the 101 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.66 vs. HOLX: 21.45 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
HOLX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 4.8  Med: 6.9 Max: 25.4
Current: 21.45
4.8
25.4

More Statistics

Revenue (TTM) (Mil) $3,207.30
EPS (TTM) $ -0.31
Beta0.83
Volatility20.91%
52-Week Range $35.10 - 45.09
Shares Outstanding (Mil)272.12

Analyst Estimate

Sep18 Sep19 Sep20
Revenue (Mil $) 3,209 3,316 3,390
EBIT (Mil $) -143 685
EBITDA (Mil $) 793 1,094 1,111
EPS ($) -0.13 1.44 2.48
EPS without NRI ($) -0.13 1.44 2.48
EPS Growth Rate
(Future 3Y To 5Y Estimate)
-1.99%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}